Detailed Study of the Pulmonary Arterial Hypertension-Pipeline Review, H2 2016

Pulmonary Arterial Hypertension-Pipeline Review, H2 2016 ​is a new market research publication announced by Reportstack. This report provides an overview of the Pulmonary Arterial Hypertension pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Pulmonary Arterial Hypertension, complete with analysis by stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pulmonary Arterial Hypertension and features dormant and discontinued projects.

Complete report available @ Pulmonary Arterial Hypertension-Pipeline Review, H2 2016

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape of Pulmonary Arterial Hypertension
- The report reviews pipeline therapeutics for Pulmonary Arterial Hypertension by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report reviews key players involved Pulmonary Arterial Hypertension therapeutics and enlists all their major and minor projects
- The report assesses Pulmonary Arterial Hypertension therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Pulmonary Arterial Hypertension

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Pulmonary Arterial Hypertension
- Devise corrective measures for pipeline projects by understanding Pulmonary Arterial Hypertension pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies Mentioned

Actelion Ltd APT Therapeutics, Inc. Arena Pharmaceuticals, Inc. Ascendis Pharma A/S AVEO Pharmaceuticals, Inc. Bial - Portela & Ca, S.A. Celsion Corporation Celtaxsys, Inc. Chugai Pharmaceutical Co., Ltd. Complexa, Inc. Eli Lilly and Company Galectin Therapeutics, Inc. Gilead Sciences, Inc. Hanmi Pharmaceuticals, Co. Ltd. HitGen LTD Insmed Incorporated INVENT Pharmaceuticals, Inc. Johnson & Johnson Kowa Company, Ltd. Mast Therapeutics, Inc. Mezzion Pharma Co. Ltd. miRagen Therapeutics, Inc. Morphogen-IX Limited Nippon Kayaku Co., Ltd. Nippon Shinyaku Co., Ltd. Novartis AG Peloton Therapeutics, Inc. PhaseBio Pharmaceuticals, Inc. Pluristem Therapeutics Inc. Proteo, Inc. Pulmokine, Inc. Reata Pharmaceuticals, Inc. Respira Therapeutics, Inc. Reviva Pharmaceuticals Inc. Selten Pharma, Inc Silence Therapeutics Plc SteadyMed Therapeutics, Inc. Suda Ltd Toray Industries, Inc.

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

Reportstack Market Research

###